Esaote Wins FDA Approval for MyLab™ A50 and A70 Ultrasound Systems, Expanding U.S. Portfolio

Esaote, a global leader in medical imaging, announced that its MyLab™ A50 and MyLab™ A70 ultrasound platforms have received FDA clearance, confirming compliance with the highest standards of safety and clinical performance. Already introduced internationally, these advanced systems are now available in the United States, marking a major step in Esaote’s mission to deliver innovative diagnostic solutions worldwide.

Designed for versatility and portability, the MyLab™ A50 and A70 systems are compact, lightweight, and capable of battery operation, allowing clinicians to bring advanced ultrasound capabilities to a variety of care settings. From hospital departments to outpatient clinics and point-of-care environments, the systems are engineered to adapt to evolving mobility needs.

“The new A-series emphasizes user experience with a diverse range of interface options, including both a conventional and touch control panel,” said Thomas Will, Director of Ultrasound Sales at Esaote North America. “The devices boast an intuitive, easy-to-clean design that allows clinicians to operate efficiently and confidently.”

Both platforms are optimized to handle a wide spectrum of clinical applications, ranging from routine diagnostic imaging to advanced evaluations. Among their features are:

• Liver elastography and attenuation imaging, enabling comprehensive liver disease assessments.

• Cardiology tools, such as strain analysis, for advanced functional evaluation.

• Multiparametric imaging capabilities, providing clinicians with richer diagnostic insights.

By integrating artificial intelligence and cutting-edge imaging technologies, the MyLab™ A50 and A70 are designed to support healthcare providers in delivering faster, more precise diagnoses. Esaote emphasized that these systems enhance diagnostic confidence while supporting workflow efficiency across specialties.

The FDA clearance represents not just a product milestone but also a reinforcement of Esaote’s renewed brand vision, which focuses on combining innovation with compassionate care. The company highlighted that the approval supports its broader goal of improving patient outcomes by equipping healthcare professionals with tools that are intuitive, reliable, and capable of addressing modern clinical challenges.

As Esaote continues to expand its presence in the U.S. market, the MyLab™ A50 and A70 underscore the company’s commitment to delivering ultrasound systems that balance advanced functionality with accessibility and ease of use. Their adaptability makes them suitable for both high-demand hospital environments and smaller, mobile-focused practices seeking flexible diagnostic solutions.

By pairing AI-driven imaging advancements with user-centered design, Esaote’s latest A-series ultrasound systems reflect the ongoing evolution of ultrasound from a core diagnostic tool into a comprehensive, multipurpose platform for modern healthcare.